Last $0.32 USD
Change Today -0.0053 / -1.63%
Volume 923.1K
HEB On Other Exchanges
As of 3:59 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

hemispherx biopharma inc (HEB) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/23/14 - $0.55
52 Week Low
11/25/13 - $0.19
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

hemispherx biopharma inc (HEB) Related Bloomberg News

View More Bloomberg News

hemispherx biopharma inc (HEB) Related Businessweek News

No Related Businessweek News Found

hemispherx biopharma inc (HEB) Details

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Its products include Ampligen, which is under clinical development for the treatment of Chronic Fatigue Syndrome, Hepatitis B, human immunodeficiency virus (HIV), renal cell carcinoma, and malignant melanoma; Alferon N Injection, an injectable formulation of natural alpha interferon for the treatment of certain categories of genital warts; and Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of influenza and other emerging viral diseases. Hemispherx Biopharma, Inc. was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.

39 Employees
Last Reported Date: 03/14/14
Founded in 1990

hemispherx biopharma inc (HEB) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.0M
Executive Vice Chairman, Chief Financial Offi...
Total Annual Compensation: $553.8K
Chief Medical Officer and Medical Director
Total Annual Compensation: $265.5K
Compensation as of Fiscal Year 2013.

hemispherx biopharma inc (HEB) Key Developments

Hemispherx Biopharma Announces Earnings Results for the Year Ended December 31, 2013

Hemispherx Biopharma announced earnings results for the year ended December 31, 2013. Net loss for 2013 twelve month period (including non-cash effects) was approximately $16,225,000 or $0.10 per share as compared to a net loss of $17,354,000 or $0.12 per share for the same period in 2012. This year-to-year decrease in net loss was approximately $1,129,000 or 7%.

Hemispherx Biopharma Wins Federal Lawsuit Regarding Investment Banking Fees

Hemispherx Biopharma, Inc. announced that after more than a week in trial, a federal jury in Atlanta took only an hour to determine there was no merit to a brokerage firm's claim that Hemispherx owed the firm over $6 million for commissions from private sales of stock in 2009. MidSouth Capital, Inc., sued Hemispherx in 2010 for commissions it claimed it was due under the terms of a 2008 contract which Hemispherx never signed. Investment bank Rodman & Renshaw sold more than $31 million worth of Hemispherx stock in mid-2009. Rodman & Renshaw was promptly paid the commission it was due under the terms of its engagement agreement. MidSouth, whose brokers, Rob Rosenstein and Adam Cabibi, were terminated after they failed to secure a closing on several failed convertible debenture proposals, also demanded payment of a commission on the subsequent Rodman & Renshaw stock sale.

Hemispherx Biopharma, Inc. Partners with GP Pharm Plans on Making Applications in Chile, Peru and Uruguay for Regulatory Approval of Ampligen to Treat CFS

Hemispherx Biopharma, Inc. announced that it and its partner GP Pharm are planning on making applications in Chile, Peru and Uruguay for regulatory approval of Ampligen to treat CFS.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HEB:US $0.32 USD -0.0053

HEB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $197.39 USD -1.99
AstraZeneca PLC 3,782 GBp +23.00
Baxter International Inc $72.81 USD -0.64
Medigene AG €4.46 EUR -0.29
Sarepta Therapeutics Inc $24.40 USD +0.17
View Industry Companies

Industry Analysis


Industry Average

Valuation HEB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 364.1x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 267.3x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HEMISPHERX BIOPHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at